6Younes A, Bartlett NL, Leonard JP, et al. Brentuximab Ve-dotin (SGN-35) for Relapsed CD30-Positive Lymphomas[J].Thenew England journal of medicine,2010,363(19):1812-1821.
7Helene S. EU Compassionate Use Programmes (CUPs): regula-tory framework and points to consider before CUP implemen-taion[J]. Pharm Med, 2010,24(4):223-229.
8Younes A,Gopal AK, Smith SE,et al. Results of a pivotalphase II study of brentuximab Vedotin for patients with re-lapsed or refractory Hodgkinys lymphoma[J]. Journal of clinicaloncology,2012,30(18):2183-2189.